CarterBaldwin partner appointed to the board of the Georgia branch of the Juvenile Diabetes Research Foundation (JDRF)

//CarterBaldwin partner appointed to the board of the Georgia branch of the Juvenile Diabetes Research Foundation (JDRF)

CarterBaldwin partner appointed to the board of the Georgia branch of the Juvenile Diabetes Research Foundation (JDRF)

2018-08-31T03:14:08+00:00By |

CarterBaldwin Executive Search is pleased to announce that Jennifer Sobocinski has been appointed to the board of the Georgia branch of the Juvenile Diabetes Research Foundation (JDRF).

Jennifer is a Founding Partner of CarterBaldwin and leads the firm’s industrial and technology practices. She has been involved in the JDRF community since her son was diagnosed with type 1 diabetes four years ago.

“I’m excited to join the JDRF Georgia Board. I’m fortunate to have the opportunity to work with such a passionate group of people who are all dedicated to helping those living with this difficult, lifelong disease. I’m hopeful that through our efforts, children—like my son—will be able to live longer and without the terrible consequences that face so many adults with type 1 diabetes.”

Prior to this appointment, Jennifer served a seven-year term on the Board of Women in Technology (WIT).  She also volunteers her time at her children’s elementary school, where she is on the board of the parent teacher organization.

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF works every day to change the reality of this disease for millions of people—and to prevent anyone else from ever knowing it—by funding research, advocating for government support of research and new therapies, ensuring new therapies come to market and connecting and engaging the T1D community. Founded by parents determined to find a cure for their children with T1D, JDRF has expanded through grassroots fundraising and advocacy efforts to become a powerhouse in the scientific community with dozens of U.S. locations and six international affiliates. They have funded more than $2 billion in research to date and made significant progress in understanding and fighting the disease.